MYCO-004

MYCO-004 is an investigational **psychedelic small-molecule tryptamine analog** being developed by **Mydecine Innovations Group** for psychiatric disorders, with the clearest disclosed focus on **substance use disorder** and **smoking cessation**. Public descriptions characterize it as a **second-generation, psilocybin-derived compound** with patent-pending structural modifications intended to improve pharmacokinetic control, uptake time, scalability, and long-term stability relative to first-generation psilocybin products. It has been described as a **transdermal patch-delivered formulation** designed for **precision dosing** and a relatively **short psychedelic session duration of about 2 hours**. The exact chemical structure and receptor pharmacology have not been publicly disclosed, but based on its characterization as a psychedelic tryptamine derived from psilocybin, it is likely intended to act through serotonergic psychedelic pathways typical of this class. As publicly described in 2021 and 2022 materials, MYCO-004 remained in the **preclinical** stage with plans for Phase 1 development.